ME - Utang jangka dawa perusahaan 23andMe Inc.

The business of 23andMe Holding Co. (ME) is in a deep managerial deadlock due to a conflict between top management and the board of directors, which calls the transparency of processes into question. Revenue is generated through the sale of genetic tests and by providing pharma giants with access to data arrays. This price chart, which serves as confirmation of the market valuation, reflects a debt load at the level of 0.04. The foundation of its stability is a colossal archive of biodata, which creates a powerful defensive barrier against competitors.

Long-term debt reflects the market value of 23andMe Holding Co. (ME) obligations with maturities exceeding one year. By analyzing this long-term debt chart, an investor can determine the volume of external financing allocated for strategic development. This metric measures the stability of the liability structure within a fundamental valuation. For a company with a high cash burn rate in biotechnology, this indicator is critical. Rising debt amid depleting liquidity signals increased insolvency risks.